for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ADMA Biologics Inc

ADMA.OQ

Latest Trade

4.69USD

Change

0.21(+4.69%)

Volume

48,038

Today's Range

4.35

 - 

4.69

52 Week Range

2.08

 - 

6.31

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.48
Open
4.48
Volume
48,038
3M AVG Volume
16.25
Today's High
4.69
Today's Low
4.35
52 Week High
6.31
52 Week Low
2.08
Shares Out (MIL)
59.32
Market Cap (MIL)
265.74
Forward P/E
-4.42
Dividend (Yield %)
--

Latest Developments

More

Adma Biologics Files For Mixed Shelf Of Upto $200 Mln - SEC Filing

ADMA Biologics Q2 Loss Per Share $0.25

Adma Biologics Receives FDA Approval For License Transfers For Bivigam And Nabi-Hb

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ADMA Biologics Inc

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Industry

Biotechnology & Drugs

Contact Info

C/O Adma Biologics

Inc., 465 State Route 17

+1.201.4785552

https://www.admabiologics.com/

Executive Leadership

Steven A. Elms

Chairman of the Board

Adam S. Grossman

President, Chief Executive Officer, Co-Founder, Director

Jerrold B. Grossman

Vice Chairman of the Board, Co-Founder

Brian Lenz

Chief Financial Officer, Executive Vice President

James Mond

Chief Scientific and Medical Officer

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.610

2017

-1.650

2018

-1.450

2019(E)

-1.013
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.46
Price To Book (MRQ)
5.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
179.08
LT Debt To Equity (MRQ)
178.60
Return on Investment (TTM)
-48.74
Return on Equity (TTM)
-45.55

Latest News

Latest News

UPDATE 1-FDA declines to approve re-launch of ADMA Biologics' Bivigam

The U.S. Food and Drug Administration (FDA)on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said.

FDA declines to approve re-launch of ADMA Biologics' Bivigam

The U.S. Food and Drug Administration on Wednesday declined to approve ADMA Biologics Inc's application to re-launch its immune deficiency treatment Bivigam, the company said.

BRIEF-ADMA Biologics Files For Mixed Shelf Offering Of Up To $100 Mln

* ADMA BIOLOGICS FILES FOR MIXED SHELF OFFERING OF UP TO $100 MILLION - SEC FILING Source http://bit.ly/2IrSugh Further company coverage:

BRIEF-ADMA Biologics Retires About 8.6 Million Shares Previously Issued to Biotest

* ADMA BIOLOGICS INC - RETIRES APPROXIMATELY 8.6 MILLION SHARES PREVIOUSLY ISSUED TO BIOTEST PHARMACEUTICALS CORPORATION AND ITS FORMER PARENT, BIOTEST AG

BRIEF-ADMA Biologics Releases Its First Commercial Batch Of Nabi-HB Manufactured Under Its Ownership

* ADMA BIOLOGICS ANNOUNCES THE RELEASE OF ITS FIRST COMMERCIAL BATCH OF NABI-HB MANUFACTURED UNDER ITS OWNERSHIP

BRIEF-ADMA Files Biologics License Application For Its Third Plasma Collection Center

* ADMA FILES BIOLOGICS LICENSE APPLICATION FOR ITS THIRD PLASMA COLLECTION CENTER

BRIEF-Adma Biologics prices follow-on offering of 17.0 mln shares

* Adma Biologics Inc - pricing of offering of approximately 17.0 million shares of its common stock at price of $2.15 per share Source text for Eikon: Further company coverage:

BRIEF-ADMA Biologics now sees offering of 13.6 mln shares of common stock - SEC filing

* Now sees offering of 13.6 million shares of its common stock, up from previous filing of 10.2 million shares - SEC filing Source text: (http://bit.ly/2zmNV1L) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-ADMA Biologics Q3 loss per share $0.59

* ADMA Biologics provides corporate update and reports third quarter 2017 financial results

BRIEF-ADMA Biologics says ‍loss per share was $0.59 for fiscal quarter ended Sept 30​

* ADMA Biologics Inc says for fiscal quarter ended September 30, loss per share was $0.59 - SEC filing

BRIEF-Adma Biologics Inc files for offering of up to $28.75 million of common stock

* Adma Biologics Inc files for offering of up to $28.75 million of common stock Source text: (http://bit.ly/2gvC2f8) Further company coverage:

BRIEF-ADMA Biologics ‍enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset Management​

* ADMA Biologics Inc - entered into a credit agreement for up to $40 million with affiliated entities of marathon asset management

BRIEF-ADMA Biologics Q2 loss per share $0.55

* ADMA Biologics provides corporate update and reports second quarter 2017 financial results

BRIEF-U.S. Patent and Trademark Office issues immunotehrapy patent to Adma Biologics

* Adma Biologics - U.S. Patent and trademark office has issued to co U.S. Patent no. 9,714,283 which encompasses methods of providing immunotherapy to patients

BRIEF-ADMA Biologics provides corporate timeline and activities update

* ADMA Biologics provides corporate timeline and activities update to stockholders

BRIEF-ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock

* ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock by the selling shareholders Source text: (http://bit.ly/2twQ4Bo) Further company coverage:

BRIEF-Biotest ‍sells US therapy business to Adma Biologics, Inc.​

* RECEIVES ALSO DISTRIBUTION RIGHTS OF SPECIFIED CURRENT PRODUCT AND A RIGHT OF FIRST OFFER FOR DISTRIBUTION OF FUTURE PRODUCTS OF ADMA FOR EUROPE, NEAR AND MIDDLE EAST AND SELECTED ASIAN COUNTRIES

BRIEF-ADMA Biologics Q1 loss per share $0.51

* ADMA Biologics provides corporate update and reports first quarter 2017 financial results

BRIEF-ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals Corp

* ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals Corporation and become a vertically integrated commercial plasma products company

BRIEF-Biotest to sell US therapy business to ADMA Biologics Inc.

* Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up